Healthcare Services

Increasing Adoption Of Next-Generation Antibody Therapeutics Is A Vital Solution In Addressing The Surge Of Chronic Diseases Is Influencing The Next-Generation Antibody Therapeutics Market

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Increase In Market Value Is Predicted For The Next-Generation Antibody Therapeutics Market During The 2026–2030 Period?

The next-generation antibody therapeutics market has experienced rapid growth in recent years. It is anticipated to increase from $7.56 billion in 2025 to $8.35 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.4%. Historically, this expansion can be attributed to several factors, including an increase in monoclonal antibody approvals, the growing prevalence of cancer, the expansion of biologics manufacturing capacity, rising investment in pharmaceutical R&D, and improved regulatory pathways for biologics.

The next-generation antibody therapeutics market is anticipated to experience substantial growth in the upcoming years, projected to reach $12.63 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.9%. This expansion during the forecast period is driven by progress in antibody engineering technologies, a heightened demand for targeted therapies, the escalating prevalence of chronic and autoimmune diseases, the broadening of clinical trials into emerging markets, and increasing collaborations between biotechnology and pharmaceutical firms. Key trends anticipated during this period encompass the development of bispecific and multispecific antibody platforms, the rising uptake of antibody-drug conjugates in oncology, an intensified focus on high-affinity and long-acting antibodies, an expanding clinical pipeline for rare and orphan diseases, and a move towards personalized antibody-based therapies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12678&type=smp

What Primary Factors Are Fueling The Expansion Of The Next-Generation Antibody Therapeutics Market?

The rising occurrence of chronic illnesses is anticipated to boost the expansion of the next-generation antibody therapeutics market in the future. These are health conditions enduring a year or more, necessitating ongoing medical attention, limiting daily functions, or both. Next-generation antibody treatments offer a therapeutic role for chronic disease sufferers, providing more targeted interventions that improve patient outcomes. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, it was projected that by the year 2050, the number of individuals aged 50 years and older who have at least one chronic illness will surge by 99.5%, rising to 142.66 million. Consequently, the growing incidence of chronic diseases is propelling the expansion of the next-generation antibody therapeutics market.

How Is The Next-Generation Antibody Therapeutics Market Distributed Across Key Segments?

The next-generation antibody therapeutics market covered in this report is segmented –

1) By Types Of Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Types

2) By Therapeutic Area: Oncology, Autoimmune Diseases, Infectious Diseases, Neurodegenerative Disorders, Other Therapeutic Areas

3) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By Monoclonal Antibodies: IgG Monoclonal Antibodies, IgM Monoclonal Antibodies

2) By Polyclonal Antibodies: Serum-Derived Polyclonal Antibodies, Hybridoma-Derived Polyclonal Antibodies

3) By Bispecific Antibodies: Dual-Targeting Antibodies, Single-Chain Variable Fragment (scFv) Antibodies

4) By Antibody-Drug Conjugates (ADCs): Targeted ADCs, Payload Types

5) By Other Types: Nanobodies, Engineered Antibodies

What Trends Are Shaping The Next-Generation Antibody Therapeutics Market Structure?

Leading companies in the next-generation sequencing (NGS) sample preparation market are increasingly focusing on automating sample preparation, employing technologies such as digital microfluidics platforms. This strategic shift aims to improve efficiency, lessen manual errors, and streamline sample processing to achieve more precise and timely genomic analysis. Digital microfluidics platforms are advanced systems that manipulate small volumes of fluids on a microchip using electrical fields, facilitating accurate and automated handling of samples for applications like NGS sample preparation. For example, in September 2023, INTEGRA Biosciences, a Switzerland-based provider of intuitive solutions for liquid handling and media preparation, introduced the MIRO CANVAS. This compact digital microfluidics platform is designed for fully automated next-generation sequencing (NGS) sample preparation. This innovative system enhances both accuracy and efficiency by automating workflows, reducing the required hands-on time to just 15 minutes per run, and enabling immediate processing of clinical specimens. The MIRO CANVAS seeks to simplify NGS procedures and support advanced genomics research by preserving DNA integrity and minimizing reagent usage.

Who Are The Leading Firms Participating In The Next-Generation Antibody Therapeutics Market?

Major companies operating in the next-generation antibody therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc., Genmab A/S, Zymeworks Inc., NBE-Therapeutics AG, Daiichi Sankyo Company Limited, Merck & Co Inc., Novartis AG, AbCellera Biologics Inc., Sotio Biotech, F-Star Therapeutics Ltd., ADC Therapeutics SA, Harbour BioMed

Access The Complete Next-Generation Antibody Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

Which Region Commands The Largest Share Of The Next-Generation Antibody Therapeutics Market?

North America was the largest region in the next-generation antibody therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Next-Generation Antibody Therapeutics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12678&type=smp

Browse Through More Reports Similar to the Global Next-Generation Antibody Therapeutics Market 2026, By The Business Research Company

Next Generation Sequencing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-sequencing-global-market-report

Next Generation Military Power Supply Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-military-power-supply-global-market-report

Next Generation Computing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-computing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795